Spoken Alpha
QNCX
Quince Therapeutics, Inc.
Overview
Quince Therapeutics develops the AIDE technology platform, a drug-device combination that encapsulates drugs into patients' own red blood cells for improved drug delivery to treat rare diseases. The company's lead candidate, eDSP, failed to meet primary endpoints in a Phase 3 trial for ataxia-telangiectasia and is no longer in development.
Quince Therapeutics, Inc is a Healthcare company operating in Biotechnology with a $16.7M market cap.
Most recent reported earnings: Q2 FY2026 (Aug 9, 2026).
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Extracted from Unknown source, 2026-06-21.
Transcripts
Recent earnings calls
No earnings calls indexed for QNCX yet
We index calls for roughly 3,000 US-listed companies. If you'd like us to add QNCX, reply to your welcome email and we'll prioritize it.
History
Earnings history
- Q2 FY20262026-08-09EPS— vs ——Rev— vs ——EODHD
- Q1 FY20262026-05-18EPS$57.60 vs $-52.00+100.0%Rev$0 vs ——EODHD
- Q4 FY20252026-03-02EPS$-0.41 vs $-0.18-100.0%Rev$0 vs ——EODHD
- Q3 FY20252025-11-12EPS$-0.25 vs $-0.22-13.6%Rev$0 vs ——EODHD
- Q2 FY20252025-08-10EPS$-0.34 vs $-0.26-30.8%Rev$0 vs ——EODHD
- Q1 FY20252025-05-11EPS$-0.34 vs $-0.23-47.8%Rev$0 vs ——EODHD
- Q4 FY20242025-03-30EPS$-0.28 vs $-0.10-100.0%Rev$168.0K vs ——EODHD
- Q3 FY20242024-11-11EPS$-0.13 vs $-0.10-27.2%Rev$0 vs ——EODHD
- Q2 FY20242024-08-12EPS$-0.64 vs ——Rev$0 vs ——EODHD
- Q1 FY20242024-03-31EPS$-0.22 vs ——Rev$36.0K vs ——EODHD
- Q4 FY20232024-02-13EPS$-0.22 vs $-0.28+21.4%Rev$0 vs ——EODHD
- Q3 FY20232023-11-13EPS$-0.15 vs ——Rev$0 vs ——EODHD
- Q2 FY20232023-08-02EPS$-0.14 vs $0.00—Rev$0 vs ——EODHD
- Q1 FY20232023-05-14EPS$-0.34 vs $-0.31-10.5%Rev$0 vs ——EODHD
- Q4 FY20222023-03-14EPS$-0.15 vs $-0.29+47.8%Rev$0 vs ——EODHD
- Q3 FY20222022-11-08EPS$-0.22 vs $-0.28+21.4%Rev$0 vs ——EODHD
- Q2 FY20222022-08-08EPS$-0.51 vs $-0.48-6.3%Rev$0 vs ——EODHD
- Q1 FY20222022-05-09EPS$-0.72 vs $-0.55-30.9%Rev$0 vs ——EODHD
- Q4 FY20212022-02-28EPS$-0.78 vs $-0.65-20.0%Rev$0 vs ——EODHD
- Q3 FY20212021-10-28EPS$-0.73 vs $-0.74+1.4%Rev$0 vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-09 | — | — | — | — | — | — | EODHD |
| Q1 FY2026 | 2026-05-18 | $57.60 | $-52.00 | +100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-02 | $-0.41 | $-0.18 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-12 | $-0.25 | $-0.22 | -13.6% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-10 | $-0.34 | $-0.26 | -30.8% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-11 | $-0.34 | $-0.23 | -47.8% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-30 | $-0.28 | $-0.10 | -100.0% | $168.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.13 | $-0.10 | -27.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-12 | $-0.64 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-03-31 | $-0.22 | — | — | $36.0K | — | — | EODHD |
| Q4 FY2023 | 2024-02-13 | $-0.22 | $-0.28 | +21.4% | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.15 | — | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-02 | $-0.14 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.34 | $-0.31 | -10.5% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-14 | $-0.15 | $-0.29 | +47.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-08 | $-0.22 | $-0.28 | +21.4% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-08 | $-0.51 | $-0.48 | -6.3% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-09 | $-0.72 | $-0.55 | -30.9% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-02-28 | $-0.78 | $-0.65 | -20.0% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-10-28 | $-0.73 | $-0.74 | +1.4% | $0 | — | — | EODHD |
Source: EODHD. QNCX reported actuals as published; sparse fields render as —.
Track Record
SampleSpoken Alpha tracks QNCX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters but stock falls 60% of the time
SampleWhen a company consistently beats but the stock doesn't react, consensus is usually set too low or the buy-side number is materially above sell-side. Watch for guidance walk-downs ahead of the print.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
Quarterly beats & misses
Sample| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $4.68 | $3.99 | +17.4% | +1.8% | +3.7% |
| Q4 FY2026 | $4.61 | $4.02 | +14.8% | -0.7% | -2.2% |
| Q3 FY2026 | $4.38 | $4.17 | +5.0% | -3.7% | -4.8% |
| Q2 FY2026 | $4.39 | $4.13 | +6.2% | -5.7% | -7.0% |
| Q1 FY2025 | $4.74 | $3.97 | +19.4% | -6.6% | -5.4% |
| Q4 FY2025 | $4.59 | $4.04 | +13.6% | +4.4% | +5.1% |
| Q3 FY2025 | $4.70 | $4.09 | +15.0% | +4.2% | +6.3% |
| Q2 FY2025 | $4.74 | $4.07 | +16.4% | -5.7% | -4.6% |
| Q1 FY2024 | $4.88 | $4.12 | +18.5% | -5.1% | -7.9% |
| Q4 FY2024 | $4.39 | $4.17 | +5.2% | +0.7% | +3.7% |
Guidance change history
Sample- Q1 FY2026Raised2026-04-15
- Q4 FY2026Raised2026-13-15
- Q3 FY2026Raised2026-10-15
- Q2 FY2026Raised2026-07-15
- Q1 FY2025Raised2025-04-15
- Q4 FY2025Raised2025-13-15
- Q3 FY2025Raised2025-10-15
- Q2 FY2025Raised2025-07-15
Top executives
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
- Dirk ThyeCEO1 yr 1 mono recorded callsCurrentSample
CEO since 2025 • 3/4 beats (75%) • guidance suspended Q1 FY2026
- Charles S RyanPresident2 yr 10 mono recorded callsCurrentSample
PRESIDENT since 2023 • 9/12 beats (75%) • guidance suspended Q3 FY2026
- Brendan HannahCOO1 yr 1 mono recorded callsCurrentSample
COO since 2025 • 3/4 beats (75%) • last guidance raise Q2 FY2026
- Brigette RobertsChief Corp. Affairs Officer2 mono recorded callsCurrentSample
OTHER since 2026 • 1/2 beats (50%) • last call held guidance Q3 FY2026
- Christopher P LoweCEO0 mono recorded callsFormerSample
CEO since 2022 • 8/16 beats (50%) • guidance suspended Q2 FY2026
- Casey LynchCEO2 yr 8 mono recorded callsFormerSample
CEO since 2019 • 24/28 beats (86%) • last guidance raise Q2 FY2026
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for QNCX.
$ curl https://api.spokenalpha.com/v1/companies/QNCXFAQ
Frequently asked about QNCX
Where can I find Quince Therapeutics, Inc.'s (QNCX) earnings call transcripts?
Spoken Alpha indexes QNCX's earnings call transcripts at https://spokenalpha.com/companies/QNCX. Each call links to attributed speakers and parsed analyst Q&A. Quince Therapeutics, Inc.'s own investor relations page is at https://ir.quincetx.com/.
What sector is QNCX in?
Quince Therapeutics, Inc. (QNCX) operates in the Healthcare sector (Biotechnology industry).